Institutional
Column Group LLC
CIK 0001833486
$100.7M
Reported AUM
3
Positions
Q1 2026
Period
2026-05-18
Filed
The Brief · Column Group LLC · Q1 2026
AI · grounded in 13F
Column Group LLC closed its position in Tenaya Therapeutics, Inc. TNYA, reducing its holdings by $6.69M. The fund also exited its position in RAPT Therapeutics Inc, resulting in a $5.29M decrease. Conversely, the fund accumulated shares of Surrozen, Inc., increasing its position by 3.54%.
Portfolio · Q1 2026
Top holdings
QoQ vs Q4 2025
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | — | Surrozen, Inc. | — | — | — | — | $55.8M | 55.45% | +65,600 | +3.5% |
| 2 | ORIC | ORIC Pharmaceuticals Inc. | $7.50 | -6.48% | -19.53% | -54.95% | $44.9M | 44.55% | — | HELD |
| 3 | RVMD | Revolution Medicines Inc | $149.23 | -4.15% | 263.18% | 421.05% | $4K | 0.00% | — | HELD |
| 4 | TNYA | Tenaya Therapeutics, Inc. | $0.68 | -6.18% | 14.84% | -96.40% | — | — | −9,400,290 | EXITED |
| 5 | — | RAPT Therapeutics Inc | — | — | — | — | — | — | −156,270 | EXITED |
Source: SEC EDGAR · accession 0001193125-26-227853. 13F discloses long positions only — shorts, foreign equities, and options are excluded.